Literature DB >> 9040723

Apomorphine responses in Parkinson's disease and the pathogenesis of motor complications.

L Verhagen Metman1, E R Locatelli, D Bravi, M M Mouradian, T N Chase.   

Abstract

We studied the contribution of basal ganglia circuitry downstream from the nigrostriatal dopaminergic system to the pathogenesis of levodopa associated motor complications by means of an apomorphine dose-response paradigm in 28 parkinsonian patients grouped according to their clinical response to levodopa therapy. With progression from the dopa-naive to the severely fluctuating dyskinetic state, apomorphine response duration shortened, the dose-response slope steepened, and the therapeutic window narrowed. Because apomorphine acts independently of the integrity of presynaptic dopaminergic neurons, our results suggest that postsynaptic alterations account mainly for the appearance of response complications. The present findings support the possibility, raised by animal model studies, that motor response complications arise as a consequence of altered signal transduction mechanisms in striatal medium-sized neurons.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9040723     DOI: 10.1212/wnl.48.2.369

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  14 in total

1.  Parkinson's Disease: Motor Fluctuations.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  1999-03       Impact factor: 3.598

2.  Dopamine-dependent motor learning: insight into levodopa's long-duration response.

Authors:  Jeff A Beeler; Zhen Fang Huang Cao; Mazen A Kheirbek; Yunmin Ding; Jessica Koranda; Mari Murakami; Un Jung Kang; Xiaoxi Zhuang
Journal:  Ann Neurol       Date:  2010-05       Impact factor: 10.422

Review 3.  Preservation of function in Parkinson's disease: what's learning got to do with it?

Authors:  Jeff A Beeler
Journal:  Brain Res       Date:  2011-09-29       Impact factor: 3.252

Review 4.  The significance of continuous dopaminergic stimulation in the treatment of Parkinson's disease.

Authors:  T N Chase
Journal:  Drugs       Date:  1998       Impact factor: 9.546

Review 5.  Levodopa in Parkinson's disease: neurotoxicity issue laid to rest?

Authors:  M G Murer; R Raisman-Vozari; O Gershanik
Journal:  Drug Saf       Date:  1999-11       Impact factor: 5.606

6.  Serotonin transporter inhibition attenuates l-DOPA-induced dyskinesia without compromising l-DOPA efficacy in hemi-parkinsonian rats.

Authors:  Christopher Bishop; Jessica A George; William Buchta; Adam A Goldenberg; Mohamed Mohamed; Sando O Dickinson; Satie Eissa; Karen L Eskow Jaunarajs
Journal:  Eur J Neurosci       Date:  2012-07-05       Impact factor: 3.386

Review 7.  Pharmacokinetic-pharmacodynamic relationships of apomorphine in patients with Parkinson's disease.

Authors:  C Neef; T van Laar
Journal:  Clin Pharmacokinet       Date:  1999-09       Impact factor: 6.447

8.  Impaired gastric myoelectrical activity in patients with Parkinson's disease and effect of levodopa treatment.

Authors:  Ching-Liang Lu; Din-E Shan; Chih-Yen Chen; Jiing-Chyuan Luo; Full-Young Chang; Shou-Dong Lee; Han-Chang Wu; J D Z Chen
Journal:  Dig Dis Sci       Date:  2004-05       Impact factor: 3.199

Review 9.  Subcutaneous apomorphine : an evidence-based review of its use in Parkinson's disease.

Authors:  Dirk Deleu; Yolande Hanssens; Margaret G Northway
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

10.  Mathematical insights into the effects of levodopa.

Authors:  Michael C Reed; H Frederik Nijhout; Janet A Best
Journal:  Front Integr Neurosci       Date:  2012-07-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.